GALECTIN THERAPEUTICS INC. - COMMON STOCK

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

13 ноя 2023 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

03 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

23 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

12 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis

03 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

26 сен 2023 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

11 сен 2023 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

07 сен 2023 11:00:00 Источник Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

14 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

15 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

27 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

18 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

30 мар 2023 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

16 мар 2023 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

02 мар 2023 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

24 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

05 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

29 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

28 ноя 2022 07:00:00 Источник Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

14 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire